{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:54:22Z","timestamp":1790074462518,"version":"4.0.1"},"reference-count":79,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T00:00:00Z","timestamp":1240531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Histopathology"],"published-print":{"date-parts":[[2009,5]]},"abstract":"<jats:p><jats:bold>Aims:\u2002<\/jats:bold> Histone deacetylase (HDAC) inhibitors are novel therapeutics in the treatment of peripheral T\u2010cell lymphoma, unspecified (PTCL) and diffuse large B\u2010cell lymphoma (DLBCL), where, for unknown reasons, T\u2010cell malignancies appear to be more sensitive than B\u2010cell malignancies. The aim was to determine HDAC expression in DLBCL and PTCL which has not previously been investigated.<\/jats:p><jats:p><jats:bold>Methods and results:\u2002<\/jats:bold> The expression of HDAC1, HDAC2, HDAC6 and acetylated histone H4 was examined immunohistochemically in 31 DLBCL and 45 PTCL. All four markers showed high expression in both DLBCL and PTCL compared with normal lymphoid tissue. HDAC1 was more abundantly expressed in PTCL than in DLBCL (<jats:italic>P<\/jats:italic>\u2003=\u20030.0046), whereas acetylated H4 was more frequent in DLBCL (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.0001), the latter suggesting a mechanism for T\u2010cell lymphoma sensitivity to HDAC inhibitors. Moderate to strong HDAC6 expression was significantly correlated with favourable outcome (<jats:italic>P<\/jats:italic>\u2003=\u20030.016) in DLBCL patients, whereas the opposite effect was observed in PTCL patients (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.0001). The other markers did not correlate with survival (<jats:italic>P<\/jats:italic>\u2003&gt;\u20030.05).<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> HDAC1, HDAC2, HDAC6 and acetylated H4 are overexpressed in DLBCL and PTCL relative to normal lymphoid tissue. Furthermore, HDAC6 may be an important prognostic marker associated with favourable outcome in DLBCL and a more aggressive course in PTCL.<\/jats:p>","DOI":"10.1111\/j.1365-2559.2009.03290.x","type":"journal-article","created":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T10:23:38Z","timestamp":1240568618000},"page":"688-698","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":115,"title":["Histone deacetylase 1, 2, 6 and acetylated histone H4 in B\u2010 and T\u2010cell lymphomas"],"prefix":"10.1111","volume":"54","author":[{"given":"Lena","family":"Marquard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian B","family":"Poulsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise Mette","family":"Gjerdrum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"De Nully Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ib J","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter B","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxwell","family":"Sehested","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preben","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Ralfki\u00e6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,4,24]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"171","volume-title":"Pathology and genetics: tumours of haematopoietic and lymphoid tissues","author":"Gatter KC","year":"2001"},{"key":"e_1_2_6_3_2","first-page":"191","volume-title":"Pathology and genetics: tumours of haematopoietic and lymphoid tissues","author":"Jaffe ES","year":"2001"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2007.03.001"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1545"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800396"},{"key":"e_1_2_6_7_2","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1182\/blood.V90.1.244","article-title":"Prognostic significance of Bcl\u20102 protein expression and Bcl\u20102 gene rearrangement in diffuse aggressive non\u2010Hodgkin\u2019s lymphoma","volume":"90","author":"Gascoyne RD","year":"1997","journal-title":"Blood"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.4.945"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-015305"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2007.00976.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012914"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-09-3080"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh392"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008418727472"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0371"},{"key":"e_1_2_6_16_2","first-page":"227","volume-title":"Pathology and genetics: tumours of haematopoietic and lymphoid tissues","author":"Ralfkiaer E","year":"2001"},{"key":"e_1_2_6_17_2","article-title":"Phase II open\u2010label trial of belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T\u2010cell lymphoma. EMSO Conference","volume":"19","author":"Foss F","year":"2008","journal-title":"Ann. Onc."},{"key":"e_1_2_6_18_2","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2007.25.18_suppl.8027","article-title":"Update of the NCI multiinstitutional phase II trial of romidepsin, FK228, for patients with cutaneous or peripheral T\u2010cell lymphoma","volume":"25","author":"Piekarz RL","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"e_1_2_6_19_2","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2007.25.18_suppl.3500","article-title":"Phase I study of oral LBH589, a novel deacetylase (DAC) inhibitor in advanced solid tumors and non\u2010Hodgkin\u2019s lymphoma","volume":"25","author":"Prince HM","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"e_1_2_6_20_2","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1182\/blood.V110.11.2582.2582","article-title":"Vorinostat (suberoylanilide hydroxamic acid, SAHA) provides prolonged safety and clinical benefit to patients with advanced cutaneous T\u2010cell lymphoma (CTCL)","volume":"110","author":"Duvic M","year":"2007","journal-title":"Blood"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.9679"},{"key":"e_1_2_6_22_2","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2007.25.18_suppl.18511","article-title":"Oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in relapsed diffuse large B\u2010cell lymphoma (DLBCL): final results of a phase II trial","volume":"25","author":"Crump M","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj20021321"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.200500984"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20070779"},{"key":"e_1_2_6_26_2","first-page":"285","article-title":"The molecular mechanism of HDAC inhibitors in anticancer effects","volume":"3","author":"Bi G","year":"2006","journal-title":"Cell. Mol. Immunol."},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.2001.5639"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/pros.20022"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2001.tb02153.x"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(04)00114-X"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/35895"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/86507"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0463.2008.00957.x"},{"key":"e_1_2_6_34_2","volume-title":"World Health Organization of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues","author":"Jaffe ES","year":"2001"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2005.00429.x"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.20151"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M510023200"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0463.2005.apm_04.x"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2004.03.021"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-004-1668-2"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2005.029165"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604199"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4401567"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2003.09.043"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00494-07"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0503221102"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C500186200"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2007.04.007"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.44.28001"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.9.4868"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.17.11713"},{"key":"e_1_2_6_52_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1997.8033"},{"key":"e_1_2_6_53_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.6.2795"},{"key":"e_1_2_6_54_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M908988199"},{"key":"e_1_2_6_55_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.19.11.7816"},{"key":"e_1_2_6_56_2","doi-asserted-by":"publisher","DOI":"10.1101\/gad.14.1.55"},{"key":"e_1_2_6_57_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.191375098"},{"key":"e_1_2_6_58_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-05-0480"},{"key":"e_1_2_6_59_2","unstructured":"PelicciP MinucciS PicciniD et\u00a0al..G2M Cancer Drugs AG D assignee. Antibody tools for the diagnostic use in the medical therapy with inhibitors of histone deacetylase. Patent WO2004\/029622."},{"key":"e_1_2_6_60_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-005-6001-1"},{"key":"e_1_2_6_61_2","doi-asserted-by":"publisher","DOI":"10.1159\/000111106"},{"key":"e_1_2_6_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70004-4"},{"key":"e_1_2_6_63_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0990"},{"key":"e_1_2_6_64_2","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.e06-01-0008"},{"key":"e_1_2_6_65_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2008.03109.x"},{"key":"e_1_2_6_66_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0455"},{"key":"e_1_2_6_67_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208646"},{"key":"e_1_2_6_68_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20395"},{"key":"e_1_2_6_69_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature03672"},{"key":"e_1_2_6_70_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20154"},{"key":"e_1_2_6_71_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2005.02091.x"},{"key":"e_1_2_6_72_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0501959102"},{"key":"e_1_2_6_73_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403385"},{"key":"e_1_2_6_74_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-07-2365"},{"key":"e_1_2_6_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2004.09.030"},{"key":"e_1_2_6_76_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkj462"},{"key":"e_1_2_6_77_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.25.5.1608-1619.2005"},{"key":"e_1_2_6_78_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/26.20.4645"},{"key":"e_1_2_6_79_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.42.27695"},{"key":"e_1_2_6_80_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190310001621588"}],"container-title":["Histopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2559.2009.03290.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2559.2009.03290.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T13:09:47Z","timestamp":1697202587000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2559.2009.03290.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,24]]},"references-count":79,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["10.1111\/j.1365-2559.2009.03290.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2559.2009.03290.x","archive":["Portico"],"relation":{},"ISSN":["0309-0167","1365-2559"],"issn-type":[{"value":"0309-0167","type":"print"},{"value":"1365-2559","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,24]]},"assertion":[{"value":"2009-04-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}